key: cord-0729832-unbzp1uz
authors: Moris, Dimitrios
title: COVID-19 Among Liver Transplant Recipients
date: 2021-01-05
journal: Gastroenterology
DOI: 10.1053/j.gastro.2020.12.064
sha: 5d6acea1c29d333dd6a551634c566ed289fc87c9
doc_id: 729832
cord_uid: unbzp1uz

nan

LT patients with COVID-19 had significantly higher risk of hospitalization, but not a higher risk of mortality, thrombosis or ICU requirement compared to patients without LT and COVID-19 1 .

However, a recent analysis addressing the same question among LT and non-LT COVID-19 patients, showed no difference with regard to the proportion of hospitalizations or ICU needs 2 .

The question here is how the decision-making process of admitting patients with COVID-19 is made across different institutions and physicians. Are there any specific or universal guidelines or algorithms used to help physicians make these decisions? I suspect that the threshold to admit LT patients with COVID-19 might be lower compared to non-LT patients due to concerns that these patients might be at increased risk of adverse outcomes from COVID-19 because of coexisting comorbidities and use of immunosuppressants. Also, it is not clear from the analysis about the access of patients to telemedicine and adequate outpatient care. This will definitely vary among hospitals in the US and can affect the decision to admit patients with COVID-19 in a limited resource healthcare system 3 .

Also, the authors did not provide further insights on the low in-hospital mortality of LT COVID-19 patients in their cohort (8%) which was significantly lower than the recent analyses (17%-19% in hospitalized patients) 2, 4 and recent analyses in kidney transplant populations where inpatient mortality was even higher (19.9%) 5 . One possible explanation might be that many patients in the LT COVID-19 group were admitted in the absence of severe disease thus their chances of recovery were significantly higher.

Finally, the authors omitted to report the characteristics of LT COVID-19 patients regarding the time of COVID-19 diagnosis and the time of transplant. These findings are of paramount clinical importance and might partially explain the recovery rates in this study since due to intensive immunosuppression, recent transplant recipients (<3 months post-transplant) are expected to develop severe disease due to COVID-19 more frequently than old transplants 6 . Data from ELITA/ELTR COVID-19 registry showed that the mortality in liver transplant recipients was 16% and was higher in older recipients (>60 years old) and in patients with longer time since transplantation (>2 years) 7 .

All in all, despite the discrepancies among studies on the outcomes of transplant patients infected by COVID-19, large collaborative efforts can shed more light to many unanswered questions by providing crucial information on a potentially at-risk population, with an efficiency and scale only possible through international collaboration.

Clinical Characteristics, Hospitalization and Mortality Rates of COVID-19 Among Liver Transplant Patients in the United States: A Multi-Center Research Network Study

Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study

Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper

COVID-19 in an international European liver transplant recipient cohort

Kidney transplant recipients infected by COVID-19: Review of the initial published experience

COVID-19 and Liver Transplantation: Early Reports and Recommendations

COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry